NV-RIMINI-STREET
16.8.2016 23:01:42 CEST | Business Wire | Press release
Rimini Street, Inc. , the leading global independent provider of enterprise software support services for SAP SE’s (NYSE:SAP) Business Suite , BusinessObjects and HANA Database software and Oracle Corporation’s (NYSE:ORCL) Siebel , PeopleSoft , JD Edwards , E-Business Suite , Oracle Database , Oracle Middleware , Hyperion , Oracle Retail and Oracle Agile PLM software, today announced its expanded investment and presence in the APAC region with the launch of its local operations in South Korea. Rimini Street also announced the appointment of Sangyoul Kim as country manager, South Korea. In this newly created role, Mr. Kim is responsible for leading the growth and development in the region, which represents the twelfth largest economy in the world and a large market opportunity for the Company. Rimini Street’s expansion to South Korea is driven by strong local demand for its award-winning, premium enterprise software support that delivers a comprehensive, hyper-responsive, support alternative as compared to expensive Oracle and SAP vendor maintenance. Rimini Street’s investment in South Korea builds on the Company’s accelerating growth trajectory in the APAC region that includes a 90% increase in APAC revenue for the 12-month period ending June 30, 2016, compared with the prior 12-month period. Rimini Street’s support is available immediately for South Korean companies.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160816006207/en/
Strong Demand Drives Rimini Street Expansion into South Korea
South Korea is one of the most highly developed information and communications technology markets in the world and has been part of the Company’s planned growth strategy in the APAC region. The region is rapidly growing for Rimini Street, with a 117% increase in total signed clients to date for the 12-month period ending June 30, 2016, compared with the prior 12-month period.
Rimini Street has opened its local office in Gangnam District, Seoul, and already supports a fast-growing base of 25 clients with South Korean operations, including large established global brands such as NCH Corporation, Transaction Network Services and EBSCO. These enterprises benefit from significant annual savings compared to software vendor maintenance fees, and enjoy ultra-responsive support with an average engineer response time of less than five minutes for urgent cases.
New Leader Brings Enterprise Software and CIO Experience
As Rimini Street South Korea’s new country manager, Sangyoul Kim will lead the sales and delivery of Rimini Street’s award-winning premium software support service. Mr. Kim is a seasoned IT industry veteran with more than 20 years of experience in software implementation, software upgrades, consulting, outsourcing, sales, and delivery, working with many of South Korea’s leading IT and industrial companies.
Mr. Kim held management positions at EDS Korea and A.T. Kearney, and most recently served as executive vice president of ISTN, where he was responsible for IT service sales and delivery. He also served previously as executive vice president of DBCS, overseeing IT service sales and delivery and as the CIO of Hanwha Group, where he was responsible for strategic IT investments and innovation initiatives for more than 15 Hanwha affiliates. During his career, Mr. Kim has provided IT consulting services to many well-known South Korean companies including Samsung, Hyundai, LG, Lotte Group and Korea Telecom. Mr. Kim served as an officer in the ROK Army, and received M.S. and Ph.D. degrees in Industrial Engineering from Seoul National University.
“Economic challenges, increased global competition, and a need for growth are forcing South Korean companies to achieve cost reduction, enable business innovation and improve efficiencies. Accordingly, CIOs are finding it increasingly hard to justify the high cost of their SAP and Oracle enterprise software maintenance and support in comparison to the value received. IT leaders in South Korea want to invest in big data, cloud, IoT and other disruptive technologies to help their organizations drive greater growth, but are struggling to find the IT budgets required to make these important, game-changing investments,” said Mr. Kim. “This is why there is such strong demand for Rimini Street independent software support in South Korea as a solution to these challenges. Rimini Street is the global leader in independent maintenance services for more than a decade, proven at over 1,450 successful clients, including over 135 Fortune 500 and Fortune Global 100 clients. We look forward to enabling South Korean businesses to benefit from Rimini Street’s premium, hyper-responsive support model that provides support for a guaranteed minimum of 15 years without any required upgrades, and that can save clients up to 90 percent in total maintenance costs.”
“For over a decade, Rimini Street has been focused on developing and delivering the most robust and innovative independent software support program available today, and we are pleased to officially launch our local operations in South Korea, led by our new country manager, Sangyoul Kim. South Korea is the third largest economy in Asia, and is already demonstrating strong demand for our support services,” said Seth Ravin , CEO, Rimini Street. “We have helped numerous SAP and Oracle licensees around the world maximize their IT investments and realize greater innovation agility, and look forward to continuing our expansion and presence in accordance with our global business plan.”
To learn more, follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn .
About Rimini Street, Inc.
Rimini Street is the global leader in providing independent enterprise software support services. The company has redefined enterprise support services since 2005 with an innovative, award-winning program that enables Oracle and SAP licensees to save up to 90 percent on total support costs. Clients can remain on their current software release without any required upgrades for a minimum of 15 years. Over 1,450 global, Fortune 500, midmarket, and public sector organizations from a broad range of industries have selected Rimini Street as their trusted, independent support provider. To learn more, please visit http://www.riministreet.com .
Forward-Looking Statements
This press release may contain forward-looking statements. The words “believe,” “may,” “will,” “plan,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties, and are based on various assumptions. If the risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Rimini Street assumes no obligation to update any forward-looking statements or information, which speak only as of the date of this press release.
Rimini Street and the Rimini Street logo are trademarks of Rimini Street, Inc. All other company and product names may be trademarks of their respective owners. Copyright © 2016. All rights reserved.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160816006207/en/
Contact:
Rimini Street, Inc.
Michelle McGlocklin, +1 925-523-8414
mmcglocklin@riministreet.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
